FDA Approves First Oral Cholesterol Pill to Match Injectable Potency

The US Food and Drug Administration approved Lipfendra (enlicitide) on 16 July 2026, clearing the first oral inhibitor of a protein called PCSK9 for adults with hypercholesterolemia — a condition in which LDL, or 'bad', cholesterol is high enough to substantially raise the risk of heart attack and stroke. The drug is made by Merck, known outside the United States and Canada as MSD. Until now, treatments in the PCSK9 class had only been available as subcutaneous injections given every two to four weeks.

PCSK9 is a protein produced by the liver that effectively destroys LDL receptors — the structures that pull cholesterol out of the bloodstream. By blocking that protein, Lipfendra allows more receptors to remain active, giving the liver greater capacity to clear LDL. The injectable versions of this drug class, including evolocumab (Repatha) and alirocumab (Praluent), work through the same pathway using monoclonal antibodies. Lipfendra instead uses a different chemical architecture: a macrocyclic peptide, a compact ring-shaped molecule small enough to be absorbed through the gut.

Trial results and what they show

The FDA based its approval on two randomised, double-blind, placebo-controlled Phase 3 trials from Merck's CORALreef programme, enrolling a combined 3,207 adults already on maximally tolerated statin therapy but still requiring further LDL reduction. In the CORALreef Lipids trial, which included patients with established cardiovascular disease or high cardiovascular risk, Lipfendra reduced LDL cholesterol by a placebo-adjusted 56 percent at 24 weeks. In the CORALreef HeFH trial, targeting patients with heterozygous familial hypercholesterolemia — an inherited condition that causes dangerously elevated cholesterol from birth — the reduction reached 59 percent.

“"By harnessing the innovative science of PCSK9 inhibitors and novel macrocyclic peptide technology, Lipfendra was designed to significantly lower LDL-C in the form of a convenient once-daily pill." — Dr Dean Y. Li, President, Merck Research Laboratories”

The trials showed that adverse reaction rates were broadly comparable between patients taking Lipfendra and those on placebo. In the HeFH trial, the most commonly reported side effects were diarrhoea and dizziness. Notably, the approval trials were not cardiovascular outcomes trials — they measured LDL reduction, not whether the drug prevents heart attacks or strokes. Merck has an ongoing outcomes trial to address that question, and regulators and clinicians will be watching its results closely before drawing broader conclusions about long-term benefit.

A practical shift — but access questions remain

The practical significance of a pill formulation is considerable. The existing injectable PCSK9 inhibitors have faced persistently low uptake despite strong trial data, largely because injections require specialist initiation, cold-chain storage, and carry a psychological barrier for many patients. Lipfendra requires none of that: it is a tablet stored at room temperature, taken once daily on an empty stomach with water, black coffee, or plain tea, after which patients should wait at least 30 minutes before eating. Analysts and clinicians have suggested that removing the needle may help bring the PCSK9 class to patients who have so far been kept away by the injection format.

Pricing may partly offset that advantage. Merck has set a US list price of approximately $315 per month, or around $3,800 per year. That is meaningfully lower than the injectable PCSK9 inhibitors, which carry list prices above $6,000 annually. However, as Fierce Pharma and others have reported, prior authorisation from insurers remains standard for PCSK9 drugs in the United States, typically requiring documented proof that a patient has already tried statins at maximum tolerated doses. For international patients, Lipfendra's path to market depends entirely on separate regulatory processes: the European Medicines Agency has not yet approved the drug, and timelines for EMA review have not been announced.

“"Whether enlicitide will improve accessibility will depend on factors including pricing, insurance coverage, and how payers incorporate this medication into treatment pathways."”

A class in transition

The PCSK9 inhibitor class has long been seen as underleveraged given the strength of its evidence base. Cardiovascular outcomes trials for the injectable drugs — FOURIER for evolocumab and ODYSSEY OUTCOMES for alirocumab — each demonstrated statistically significant reductions in major cardiovascular events on top of statin therapy. The question now is whether oral delivery at a lower price will shift prescribing patterns at scale. For the estimated hundreds of millions of adults globally living with high LDL cholesterol, including those with familial hypercholesterolemia who face elevated risk from early adulthood, the arrival of an oral option represents a genuine expansion of the treatment landscape. Whether that potential translates into broader access will depend on regulators, insurers, and healthcare systems beyond the United States.

This article is free to read. It always will be — no paywall, no account, no tracking.